AKBA - Akebia Ther logo

AKBA

Akebia Ther

Akebia Therapeutics develops and commercializes therapies for kidney diseases, offering Vafseo for anemia in chronic kidney disease and Auryxia for controlling serum phosphorus. It also has clinical trials focused on cardiac surgery-related kidney injury and retinopathy.

⚕️ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago $111today

Score Overview

1 Year
Score
Net Growth-455.02%
Net TrendShrank
Net Income Consistency
Rev Growth-7.26%
Rev TrendShrank
Revenue Consistency
5 Years
Score5.2
Net Growth87.89%
Net Trend60%
Net Income Consistency
Rev Growth2.57%
Rev Trend40%
Revenue Consistency
10 Years
Score
Net Growth78.15%
Net Trend50%
Net Income Consistency
Rev Growth142x
Rev Trend50%
Revenue Consistency
All Time
Score
Net Growth19.90%
Net Trend42%
Net Income Consistency
Rev Growth312x
Rev Trend50%
Revenue Consistency

See the full market ranking →

Akebia Ther fundamental performance

Between 2020 and 2025, revenue declined from $ 295M to $ 236M and net income went from -$ 349M to -$ 5M. Revenue increased in 2 of those 5 years; net income in 3.

Across Akebia Ther's full reported history, from 2014 to 2025, revenue grew from $ 700.23K to $ 236M and net income went from -$ 37M to -$ 5M. Revenue increased in 50% of the years measured; net income in 42%.

Akebia Ther currently holds a 5-year HDB Score of 5.2 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 0.89
1 Year2025-08-12
$ 3.32-73.10%
5 Years2021-08-12
$ 2.63-66.04%
10 Years2016-08-12
$ 8.08-88.95%
All Time2014-03-20
$ 26.70-96.65%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 219M-$ 29M$ 155M
2025$ 236M-$ 5M$ 184M
2024$ 160M-$ 69M$ 51M
2023$ 194M-$ 51M$ 42M
2022$ 292M-$ 94M$ 90M
2021$ 213M-$ 244M$ 149M
2020$ 295M-$ 349M$ 269M
2019$ 335M-$ 279M$ 147M
2018$ 207M-$ 171M$ 321M
2017$ 177M-$ 76M$ 317M
2016$ 1M-$ 135M$ 260M
2015$ 0.00-$ 60M$ 138M
IPO2014$ 700.23K-$ 37M$ 108M

Explore beyond AKBA

You're looking at Akebia Ther. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies